Activin A Receptor Type IB (ACVR1B) Antibody (Center) Blocking peptide

Artikelnummer: ABT-BP7801C
Artikelname: Activin A Receptor Type IB (ACVR1B) Antibody (Center) Blocking peptide
Artikelnummer: ABT-BP7801C
Hersteller Artikelnummer: BP7801c
Alternativnummer: ABT-BP7801C-500UG
Hersteller: Abcepta
Kategorie: Proteine/Peptide
Alternative Synonym: Activin receptor type-1B, Activin receptor type IB, ACTR-IB, Activin receptor-like kinase 4, ALK-4, Serine/threonine-protein kinase receptor R2, SKR2, ACVR1B, ACVRLK4, ALK4
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with a cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. The gene for ACVR1B (activin A type IB receptor) is composed of 11 exons. Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants. The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed.
NCBI: 91
UniProt: P36896
Formulierung: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Target-Kategorie: The synthetic peptide sequence used to generate the antibody AP7801c was selected from the Center region of human ACVR1B . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.